Additionally, we found that protein expression of ZEB1, but surprisingly not MGMT, correlated with reduced survival of glioblastoma patients, as well as with shorter duration of successful TMZ therapy (Fig 6F). This evidence concerns the gene ZEB1 and glioblastoma.